Penn Bioinvestor's  Instablog

Penn Bioinvestor
Send Message
I have extensive knowledge on drug discovery, also I am interested in fundamental analysis of biotech/pharma stocks. See Seeking Alpha's policy on anonymous authors:
  • Merriman Curhan Ford Initiates Coverage on VVUS with a BUY 0 comments
    Jul 28, 2009 7:59 PM | about stocks: VVUS

    VIVUS, Inc. (NASDAQ: VVUS) ($7.43) initiated with a Buy rating by Michael King:

    • In our view, VIVUS is one of the most attractive product-driven stories in the mid-cap biotech space. The company’s valuation, at approximately $500M, is well below what we believe a company should be trading at wherein the lead product addresses a large, unmet medical need, has been substantially de-risked and to which the company holds all of the worldwide rights. Indeed, we would argue that if Qnexa was a therapy for a condition other than obesity, the shares would sell at substantially higher values.
    Stocks: VVUS
Back To Penn Bioinvestor's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.